Proteomic profiles of young adults with acute myocardial infarction by Mohamed Bakrim, Norbaiyah et al.
112 
IMJM Volume 18 No.3, December 2019 
ORIGINAL ARTICLE 
Proteomic Profiles of Young Adults with Acute 
Myocardial Infarction 
Mohamed Bakrim Na, Mohd Shah ASb, Mohd. Shah ANSb, A. Talib Nc, A.Rahman Jd, Muhamad Bunnori Ne, 
Mohd Yusri Idorusf, Zainal Abidin SKg, Abdullah Aa  
a Department of Basic Medical Sciences, Kulliyyah of Medicine, IIUM 
b Department of Internal Medicine, Kulliyyah of Medicine, IIUM 
c Department of Pathology and Laboratory Medicine, Kulliyyah of Medicine, IIUM 
d Department of Community Medicine, Kulliyyah of Medicine, IIUM 
e Department of Biotechnology, Kulliyyah of Science, IIUM. 
f Institute of Medical Molecular Biotechnology, Faculty of Medicine, UiTM Sungai Buloh  
g Department of Cardiology, Hospital Tengku Ampuan Afzan, Kuantan  
Corresponding author: 
Asst. Prof. Dr. Aszrin Abdullah  
Department of Basic Medical Sciences,  
Kulliyyah of Medicine, 
International Islamic University Malaysia, 
Jalan Sultan Ahmad Shah, 
25200 Kuantan, Pahang, Malaysia.  
Tel No: +609-5704503 
Email: draszrin@iium.edu.my  
ABSTRACT  
 
Introduction: Proteomic profiling is essential in understanding the pathophysiological process of 
multifactorial diseases such as acute myocardial infarction (AMI). Despite the increasing incidence of AMI in 
young adults, proteomic-based study focusing on young AMI remains limited. This study aimed to examine 
the plasma proteomic profiles of young adults with AMI compared to control subjects. We also hope to 
identify disease-specific protein biomarkers that contribute to the development of AMI in the young. 
Methods: Pooled plasma protein from 10 AMI patients aged 18 to 45 years and 10 age, gender and race -
matched volunteers were separated using two-dimensional electrophoresis (2-DE). The spots proteins were 
analysed using the PD Quest analysis software. The spots proteins that were found to have been expressed 
differently between the two groups were identified by Matrix Assisted Laser Desorption/Ionization Time of 
Flight (MALDI-TOF) Mass Spectrometry. Results: There were three differently expressed proteins namely 
Apolipoprotein AI (Apo AI), Apolipoprotein AIV (Apo AIV) and Haptoglobin (p < 0.05). The expressions of these 
proteins were found to be increased in young patients with AMI compared to control subjects. Conclusion: 
The up regulation of Apo AI, Apo AIV and Haptoglobin in AMI patients indicate their important roles in the 
development of atherosclerotic disease. Thus, Apo AI, Apo AIV and Haptoglobin are potential disease 
biomarkers for young AMI.                               
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INTRODUCTION 
 
Coronary artery diseases (CAD) which most 
frequently present as acute myocardial infarction 
(AMI) are the main causes of morbidity and mortality 
worldwide. It is well-known that advancing age is a 
risk factor for AMI. However, young age is no longer 
considered to be protective nowadays since the 
incidence of AMI in young adults is increasing. In the 
United States, despite a significant decline in AMI 
hospitalisations over the past four decades, there 
has been no concomitant reduction in AMI 
admissions for patients aged below 55 years.1-2  As 
for the United Kingdom, although the prevalence of 
young AMI is relatively low (3%), the rate is expected 
to rise in view of various reasons.3 Comparatively, 
the occurrence of AMI in young adults is higher in 
South Asia, with the prevalence being 16.2%, 11.7%, 
and 10.5% in Pakistan, India, and Bangladesh 
respectively.4-5 AMI also manifests a decade earlier 
in these groups of people, as compared to the 
Western populations.6  Meanwhile, 16% of all AMI 
cases that admitted into tertiary referral hospitals in 
Malaysia between 2007 and 2009 were aged less 
than 45 years for male and 55 years for female.7 
 
 
IMJM Volume 18 No.3, December 2019 
113 
There is no standard definition of ‘young’ AMI, but 
the most commonly-used cut-off age is  45 years.4,7–
13 Some studies have even employed younger cut-off 
ages like 40 and 35 years.5,14-16 The diagnosis of AMI 
at this crucial age; during which family and career 
establishment occurs, gives rise to significant 
adverse effects on the well-being and mental states 
of the patients, their families, as well as the 
community. Furthermore, the male preponderance 
of this disease results in a greater socioeconomic 
impact owing to the loss of vital human capital, 
increased burden of patient care in the families, 
and excessive usage of public healthcare facilities.13 
Many studies on AMI in young adults have mainly 
focused on the epidemiology, risk factors, and 
clinical presentations variations.4,5,8,12,15 Evidently, 
smoking has been found to be the most important 
risk factor of young AMI, whereas dyslipidaemia, 
hypertension, and diabetes had a more significant 
role in the disease among elderly patients.3,10,14,16,17 
Meanwhile for clinical characteristics, single vessel 
disease was documented to be more frequent 
among young AMI patients compared to their older 
counterparts.16-17 Despite the less extensive CAD in 
the younger patients, those reports indicated that 
CAD in young adult is associated with rapid disease 
development rather than with gradually progressing 
process.18  
 
Other than the differences in regard to the risk 
factors profiles and clinical presentations, study on 
the actual molecular changes that contribute to the 
acceleration of the pathogenesis of young AMI 
remains lacking. Recently, proteomics has become a 
valuable tool for the investigation of specific 
disease processes. The ability of proteomic profiling 
to characterise proteins that are present in diseased 
tissues is also essential to facilitate an 
understanding of the pathophysiological processes 
of individual diseases.19 Additionally, this 
technology enables the identification of proteins 
that have the potential to become diagnostic/ 
prognostic biomarkers or therapeutic target 
proteins. By virtue of the higher prevalence of AMI 
in elderly patients, previous proteomic analyses of 
AMI mainly concerned samples from this age 
group.20-22 However, elderly patients usually have 
other comorbidities that require pharmacological 
interventions, which may in turn affect the protein 
profiles. At present, proteomic-based researches on 
AMI in young adults remain limited. We hypothesize 
that beyond the discrepancies in the risk factor 
profiles and clinical presentations, the young adults 
with AMI might be associated with different 
pathophysiological changes that would be reflected 
in proteomic profiles. The study of proteomic 
profiles and the discovery of protein markers that 
are specific for young AMI will improve current 
understanding of the disease process and facilitate 
the formulation of a more age-specific preventive 
and therapeutic approach. Thus, the main objective 
of this study was to compare the proteomic profiles 
of young AMI patients relative to the controls.  
 
MATERIALS AND METHODS 
 
Subject Recruitment and Sample Collection 
 
Ten patients aged 18 to 45 years who were admitted 
to the Emergency Department of Hospital Tengku 
Ampuan Afzan (HTAA) following the diagnosis of ST-
elevated myocardial infarction (STEMI) and non ST-
elevated myocardial infarction (NSTEMI) were 
recruited. The diagnosis was confirmed by the 
presence of prolonged chest pain, typical changes in 
a 12-lead electrocardiogram (ECG) and/ or elevated 
serum creatine kinase (CK). Patients presented with 
unstable angina were excluded. Ten healthy 
volunteers who were matched for age, gender, and 
race were recruited as control subjects during 
health screening programs. AMI patients who had 
chronic illnesses like diabetes, neoplasms, 
infections, autoimmune diseases, or previous 
episode(s) of AMI were excluded from the study. 
None of the patients were on lipid-lowering agents 
or antihypertensive drugs prior to admission. 
Informed consent was obtained from all 
participants. Blood samples from                   AMI 
patients were collected in the Emergency 
Department prior to the administration                     
of Streptokinase or percutaneous coronary 
intervention (PCI) procedure to ensure the 
proteomic profiles accurately reflect the recent AMI 
instead of other invasive interventions. Some 10 ml 
of blood sample was collected from each patient 
and transferred into tubes coated with 
ethylenediaminetetra-acetic acid (EDTA). The blood 
samples were centrifuged at 2 500 revolutions per 
minute (rpm) for 10 minutes. Subsequently, the 
plasma was pipetted into 1.5 ml-micro centrifuge 
tubes and stored at -80 oC freezer pending further 
proteomic laboratory work. This research was 
conducted in accordance with the Declaration of 
Helsinki, and the study protocol was approved by 
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the Ministry of Health’s Medical Research and Ethics 
Committee (MREC), ID NMRR-16-2572-32869. 
 
Two-Dimensional Electrophoresis  
 
Some 20 µL of plasma from ten individual samples 
in each group were pooled. Highly-abundant 
proteins like albumin were removed from the 
aforementioned sample using a ProteoExtract 
Albumin Removal Kit (Merck, Darmstadt, Germany). 
The pooled samples from each group were prepared 
in triplicates to be run on three immobilised pH 
gradient (IPG) strips. A total of 500 µg of protein 
was precipitated with 300 µL of precipitating agent 
1 and 300 µL of precipitating agent 2. Following 
centrifugation at 15 000 rpm, the mixture was 
washed and air-dried as per the ReadyPrep 2-D 
Cleanup Kit (Bio-Rad) protocol.  
 
The protein pellet was resuspended in 125 µL of 
rehydration buffer [7 mol/L, 4% CHAPS, 0.2% Bio-
Lyte, 3/10 ampholyte (pH 4–7), and 0.002% 
bromophenol blue (w/v)]. The protein samples were 
loaded on 7 cm-IPG strips (Bio-Rad, ReadyStrip; pH 
4-7) and allowed to passively rehydrate for 12 
hours. Isoelectric focus was performed at a 
maximum current of 50 µA per strip at 20 oC with 
reference to the protocol of PROTEAN IEF Cell 
System (Bio-Rad). Linear and rapid voltage-ramping 
were conducted at 250 V for Step 1 and 4 000 V for 
Step 2 and 3. Prior to second dimension 
electrophoresis, the IPG strips were equilibrated for 
10 minutes with equilibrium solution I [6 M urea, 
0.375 M Tris-HCl, 2% sodium dodecyl sulphate (SDS), 
20% glycerol, 2% dithiothreitol (DDT); pH [8.8] 
followed by equilibrium solution II (Equilibirum 
solution I, in which 2% DTT was substituted with 
2.5% iodoacetamide) for another 10 minutes. The 
strips were then carefully placed on the top of the 
2-dimension gels (12% SDS-polyacylamide) with 0.5% 
agarose. Vertical 2-dimensional electrophoresis (2-
DE) was performed at a constant current of 120 V 
until the blue dye line reached the bottom of the 
gel. The gels were stained overnight with 
Coomassie Brilliant Blue R-250 stain and then de-
stained with 10% acetic acid plus 40% methanol 
until the background was acceptable clear. The 
stained gels were scanned using UMAX POWERLOOK 
1000 and the images analysed by the PD Quest 7.2.0 
2-D image analysis software (Bio-Rad). The protein 
spots that were significantly different between the 
case and control gels were manually excised from 
the gels using a biopsy punch for identification 
purposes.  
 
Mass Spectrometry and Protein Identification 
 
The protein samples were digested with trypsin. 
Their respective peptides were extracted according 
to the standard techniques and analysed using a 
Matrix Assisted Laser Desorption/Ionization Time of 
Flight (MALDI-TOF) mass spectrometer with a 5800 
Proteomic Analyser (AB Sciex).23 The proteins of 
interest were identified via comparisons with those 
in the MSPnr100 database which consisted of Homo 
sapiens as taxonomy using the Mascot (Matrix 
Science) sequence matching software. 
 
Statistical Analysis 
 
The baseline characteristics of the subjects were 
expressed as means ± standard deviations (SDs). As 
for the spots protein analysis, the intensity of each 
spot was measured in a form of optical density (OD) 
unit. Data from both groups were analysed using 
Independent Student’s T-test and the level of 
statistical significance was set at 0.05. 
 
RESULTS  
 
Baseline Characteristics  
 
Table I demonstrates the baseline characteristics of 
controls and AMI patients in the study. All subjects 
were Malay males who have been carefully matched 
for age and several risk factors. All participants were 
active smokers with insignificant difference of body 
mass index (BMI), waist circumference and total 
cholesterol levels. Young adults with AMI presented 
with significantly higher number of smoking pack-
year, fasting glucose levels and blood pressure. As 
for the family history, half of the AMI patients and 
40% of the controls had at least one first-degree 
relative who was previously diagnosed with CAD.  
 
There were more than 100 spots protein were 
detected in each two-dimensional gel using an IPG 
strip pH range of 4 to 7. The coefficients of 
correlation of the three sample gels in the same 
group were more than 0.8, hence denoting the good 
consistency of the experimental system. Figure 1 
shows the representative two-dimensional gel 
plasma map of AMI patients and the three spots tht 
were noted to be differently expressed in AMI 
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patients vis-à-vis the controls (p < 0.05). These 
proteins were expressed higher in AMI patients than 
control subjects.  
 
Table I: Baseline characteristics of all participants 
Data expressed as means (standard deviations)                     
and analysed using Independent Student’s T-test.  
*indicates a significant difference (p < 0.05). AMI: acute 
myocardial infarction, BMI: body mass index, SBP: systolic 
blood pressure, DBP: diastolic blood pressure. 
Meanwhile, Table II summarises the charactheristics 
of the three proteins as analysed by MALDI-TOF 
mass spectrometry. The proteins were identified as 
Apolipoprotein AI (Apo AI), Apolipoprotein AIV (Apo 
AIV), and Haptoglobin.  
Variables Control 
(n=10) 
AMI 
(n = 10) 
P 
value 
Age, years 
  
38.2 (3.7) 39.7 (3.7) 0.380 
BMI, kg/m2 24.9 (5.3) 25.7 (3.6) 0.712 
Waist 
circumference, 
cm 
84.6 (9.3) 88.4 (9.3) 0.384 
Current 
smokers, % 
100   100   - 
Smoking pack 
years 
5 (8) 20 (9) *0.00
3 
Total 
cholesterol, 
mmol/L 
6.3 (1.1) 5.7 (1.23) 0.146 
Blood glucose, 
mmol/L 
5.0 (0.5) 6.2 (0.5) *0.00
0 
SBP, mmHg 114 (3) 127 (19) *0.04
3 
DBP, mmHg 71 (4) 84 (13) *0.01
0 
Family history 
of CAD, % 
40   50   - 
DISCUSSION 
 
All twenty subjects in the present study were Malay 
male and active smokers with insignificant 
differences of the mean age, BMI, waist 
circumference and total cholesterol levels. In this 
study, the participants were purposely matched for 
gender, race, age and several risk factors.                      
 
This measure was taken to minimize the effects of 
confounding factors in the proteomic profiling. The 
exclusion of participants who were on anti-diabetic, 
anti-hypertensive and/or anti-hypercholesterolemia 
agents also to confirm the protein expression 
modifications observed in the profiling accurately 
reflect the pathophysiological changes in AMI instead 
of other medical conditions and drugs interaction. 
Evidently, the intake of simvastatin treatment of 
hypercholesterolemia patients modified the plasma 
expression of proteins such as fibrinogen, Apo AI and 
Haptoglobin.24  
 
The main finding of the present study was that the 
three proteins – Apo AI, Apo AIV, and Haptoglobin - 
were expressed differently in young AMI patients 
relative to healthy individuals. Apo AI is a major 
component of high-density lipoprotein (HDL); the 
former accounts for approximately 65% of the mass 
of the latter’s proteins.25-26 The up regulation of Apo 
AI in AMI patients in this study was an unexpected 
outcome as Apo AI is a known anti-atherogenic 
protein.  
 
In fact, the cardio protective effect of HDL is mainly 
attributed to the atheroprotective role of Apo AI, 
the latter of which removes excess cholesterol from 
peripheral tissues by promoting reverse cholesterol 
transport (RCT).25 Accordingly, Basak et al. (2016) 
have found that the plasma expression of Apo AI was 
reduced in stable coronary artery disease (CAD) 
patients.21 In contrast, our study observed that Apo 
AI expression was increased in young AMI patients as 
compared to the controls. These contradictory 
outcomes suggested that Apo AI might have other 
actions instead of lipid regulation alone.  
 
The increase in Apo AI expression could have been 
due to an inflammatory response secondary to the 
recent myocyte injury. Evidently, Shah et al.            
(1998) has demonstrated the anti-inflammatory              
property of Apo AI via an ApoE-null mice            
model.27 The administration of reconstituted Apo               
Figure 1: A representative two-dimensional gel             
containing plasma from acute myocardial infarction (AMI)           
patients. The spots in the 2-dimentional electrophoresis 
gels of pH 4 - 7 were examined and analysed using the PD 
Quest 7.2.0 software. Arrows denote the three spots that 
were differently expressed in young AMI patients (p < 
0.05) as compared to the controls, recognized as SSP 
1601, SSP 2501 and SSP 7201. The graph corresponds with 
the intensity of the protein in terms of optical density 
(OD). Red bars denote data from the AMI group while 
orange bars denote data from control group. 
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Table II: List of proteins that were differently expressed in AMI patients (relative to controls), as identified by 
MALDI-TOF MS 
Spot No Protein name Account no Nominal 
mass 
Calculated pI Sequence 
coverage 
Fragment 
  
  
SSP 2501 
  
Apolipoprotein 
A-I 
P012647 30759 5.56 48 % DLATVYVDVLK 
SSP 1601 
  
Apolipoprotein 
A-IV 
NP_000473.2 35344 5.28 31 % KLVPFATELHER 
SSP 7201 
  
Haptoglobin P00738 45177 6.13 8 % LRTEGDGVYTLNNEK 
MALDI-TOF MS = Matrix-assisted laser desorption/ionization of time of flight mass spectrometry. pI-isoelectric point. 
AI(Milano) particles prevented the progression of 
aortic atherosclerosis and reduced macrophage 
infiltration.27 As per another animal study, 
injections of reconstituted HDL which contained 
plasma-derived Apo AI led to a reduction in the 
expression of vascular cell adhesion molecule-1 
(VCAM-1) after the first week of arterial injury.28 
The current finding also consistent with Shao et al. 
that found the level of Apo AI chlorinated and 
oxidized with myeloperoxidase (MPO) were 
elevated in coronary artery disease (CAD) and   
acute coronary syndrome (ACS) patients.29 MPO is a   
heme protein that is expressed at high level by 
inflammatory macrophage in human atherosclerotic 
tissue. The study also reported that the elevation 
of Apo AI in CAD and ACS patients was inversely 
correlated with HDL’s cholesterol efflux capacity.29  
 
Apparently, acute inflammation may lead                       
to conversion of Apo AI from anti-inflammatory 
particles to pro inflammatory particles. 
Consistently, Ogasawara et al. have observed that 
the level of serum Apo AI bonded to oxidized low 
density lipoprotein (LDL) was higher in CAD patients 
than in the control group.30 Apo AI-LDL that was 
produced through an oxidizing reaction that occurs 
during CAD has been proposed to be a more 
sensitive inflammatory protein marker of CAD than 
C-reactive protein (CRP).30 Therefore, the elevation 
of Apo AI protein as observed in the present study 
was likely exhibiting its inflammatory protein 
function in response to the recent cardiac injury.  
 
Meanwhile, Apolipoprotein AIV (Apo AIV) is a 46 kDa 
glycoprotein that circulates in the plasma. It is also 
a part of a small, lipid-poor HDL-like particle that 
does not contain Apo AI.31 Apo AIV is also known to 
exhibit an anti-atherogenic property since acts as 
an activator of lecithin cholesterol acyl transferase 
(LCAT) during RCT.32 Apo AIV inhibits the oxidation    
of lipoprotein oxidation in the plasma, thereby 
protecting the vessel walls from radical-induced 
damage.33 Apo AIV has been reported to be 
significantly associated with stable CAD in which it 
was less expressed in CAD patients relative to the 
normal controls (7.6 ± 3.5 mg/dL vs 10.4 ± 4.1 mg/
dL; p < 0.001).34 
 
However, the current study has found that expression 
of Apo AIV in AMI patients was higher than that in the 
controls. The current finding suggested that Apo AIV 
might serve functions other than lipid metabolism 
regulation during the acute-phase response. The 
overexpression of Apo AIV could have been a form of 
response to the acute inflammatory process. This was 
consistent with the outcome of a study whereby Apo 
AIV was deemed to be a positive acute phase protein 
since there was an increase in the level of Apo AIV 
hepatic mRNA secondary to endotoxin injections.35 
Consequently, the plasma expression of Apo AIV 
increased during acute inflammation, as observed in 
our study.  
 
Another likely cause of the contradictory finding 
could have been the difference in the timing of 
sample collection. Instead of obtaining samples from 
stable CAD patients as in the former study, blood 
samples for this study were collected when the 
patients presented to the Emergency Department 
following acute clinical onset of AMI. Therefore, our 
results were more likely to reflect the Apo AIV 
changes during the acute phase reaction than that 
during the development of the disease. Another 
explanation to the contradicted finding in the trend 
of expression for Apo AIV is the difference in the            
age group of study participants being analysed. 
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Participants in previous studies were much older 
with the mean age above 60 years.34,36 Thus, the 
present study might reflect the proteomic changes 
during AMI in younger populations that possibly 
associated with more significant inflammation 
reaction. 
 
In the current study, Haptoglobin was also observed 
to be up regulated in AMI patients. It is known as an 
acute-phase reactant of non-cardiac origin that acts 
as a high-affinity haemoglobin-binding protein and 
an antioxidant. The Apolipoprotein Mortality Risk 
Study (AMORIS) Study – a large prospective trial on 
342 125 subjects – has established that Haptoglobin 
was a significant risk factor of AMI.37 In fact, the 
protein was almost as predictive of AMI as total 
cholesterol since there was a 4.2-fold increase in 
the risk of the disease in the individuals whose 
Haptoglobin levels were in the upper quartile.37 
Consistent with its role as an inflammatory marker, 
the hepatic mRNA of Haptoglobin attained a peak 
concentration 24-48 hours post-inflammation, after 
which it reassumed its basal levels within 2-7 days. 
The principal inducer of the gene expression of 
Haptoglobin was found to be a cytokine called IL-6, 
which is the main mediator of the acute-phase 
response.38  
 
The increase in Haptoglobin expression following an 
inflammatory reaction has also led to the hypothesis 
that Haptoglobin might have anti-inflammatory 
properties. This is in light of the fact that 
Haptoglobin binds to highly-toxic free haemoglobin, 
hence facilitates the removal of the latter and 
subsequently eliminating the trigger of oxidative 
tissue damage. Haas et al. (2011), who conducted 
proteomic analysis of the plasma samples of AMI 
patients, have followed-up the patients for one year 
to assess the occurrence of heart failure as per the 
New York Association (NYHA) classification.39 
According to the study, high levels of Haptoglobin 
during AMI were associated with lower NYHA grades. 
Therefore, while a high level of Haptoglobin could 
be a risk marker for AMI during the development of 
the disease, it might be beneficial post AMI owing to 
the potentially protective function of its 
peroxidase. 
 
LIMITATIONS OF THE STUDY 
 
The 2-DE proteomic analysis in this study may only 
serve as a screening for the potential proteins to be 
candidate biomarkers due to two factors; the use of 
pooled sample and the small sample size. 
Consequently, the present study did not provide 
information on the biological variations of the 
individual sample. Therefore, this primary finding 
requires further studies with larger and more 
heterogeneous sample to capture the 
environmental, genetic, and risk factors variations 
in the studied population. In addition, the 
expression of the candidate biomarkers need to be 
verified using more established proteins detection 
methods such as enzyme-linked immunosorbent 
assay (ELISA). Importantly to note that the current 
study was limited to the proteomic analysis of young 
adult with AMI in comparison to the healthy control 
in the same age group. Therefore, differential 
proteomic analysis of samples collected from young 
and elderly patients during the same timeline may 
result in better proteomic profiles comparisons 
between young AMI and older counterparts.  
 
CONCLUSION 
 
In conclusion, the up regulation of Apo AI, Apo AIV, 
and Haptoglobin in young AMI reflected their 
significant roles in the inflammatory reaction of the 
disease. These proteins could be potential protein 
biomarkers and are likely to be useful for the 
understanding of the molecular mechanisms of 
young AMI. 
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